ストックスクリーナーアプリを入手
3.22
8.00%
-0.28
アフターアワーズ：
3.22
前日終値:
$3.50
開ける：
$3.5
24時間の取引高:
32,751
Relative Volume:
2.31
時価総額：
$21.91M
収益：
-
当期純損益:
$-23.87M
株価収益率:
-0.0887
EPS:
-36.3
ネットキャッシュフロー:
$-47.63M
1週間 パフォーマンス:
+23.37%
1か月 パフォーマンス:
-7.74%
6か月 パフォーマンス:
-19.50%
1年 パフォーマンス:
-17.99%
1日の値動き範囲:
$3.22
$3.68
1週間の範囲:
$2.37
$3.68
52週間の値動き範囲:
$2.37
$9.20
Polypid Ltd Stock (PYPD) Company Profile
PYPD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.22 | 21.91M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-09-14 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-07-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 開始されました | Alliance Global Partners | Buy |
| 2020-07-21 | 開始されました | BMO Capital Markets | Outperform |
| 2020-07-21 | 開始されました | Barclays | Overweight |
| 2020-07-21 | 開始されました | Raymond James | Outperform |
すべてを表示
Polypid Ltd (PYPD) 最新ニュース
FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter
PolyPid Ltd. Announces Research and Development Collaboration with ImmunoGenesis, Inc. Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Marketscreener.com
PolyPid announces research, development collaboration with ImmunoGenesis - Yahoo Finance
PolyPid enters R&D pact with ImmunoGenesis By Investing.com - Investing.com South Africa
PolyPid stock hits 52-week low at $2.81 amid market challenges - Investing.com
PolyPid enters R&D pact with ImmunoGenesis - Investing.com India
PolyPid Collaborates with ImmunoGenesis to Boost Cancer Immunotherapy - TipRanks
PolyPid Announces Research and Development Collaboration - GlobeNewswire
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - Yahoo Finance
PolyPid Partners with ImmunoGenesis to Revolutionize Cancer Immunotherapy Drug Delivery - StockTitan
PolyPid stock touches 52-week low at $2.93 amid market challenges - Investing.com Nigeria
PolyPid Faces Nasdaq Non-Compliance Challenge - TipRanks
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance - GlobeNewswire
PolyPid Faces Nasdaq Non-Compliance, Pivotal Trial Results Due December | PYPD Stock News - StockTitan
PolyPid Ltd. (NASDAQ:PYPD) Q3 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
PolyPid Reports Q3 Results Amid SHIELD II Trial Progress - TipRanks
PolyPid Announces SHIELD II Trial Progress and Financials - TipRanks
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
PolyPid Announces $8.25 Million Share Sale Plan - TipRanks
PYPDPolyPid Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - StockTitan
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
PolyPid shares rise on strong Phase 3 prospects, gets buy rating - Investing.com Canada
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewswire
Will PolyPid Wield The SHIELD? - RTTNews
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd - GuruFocus.com
PolyPid Announces Publication in International Journal of - GlobeNewswire
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - StockTitan
PolyPid retains stock target, buy rating on positive trial enrollment update By Investing.com - Investing.com South Africa
PolyPid retains stock target, buy rating on positive trial enrollment update - Investing.com India
PolyPid completes enrollment for phase 3 trial - Investing.com
PolyPid Nears Completion of Key Phase 3 Trial - TipRanks
PolyPid Announces Last Patient In for Planned Unblinded - GlobeNewswire
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - StockTitan
PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewswire
Equities Analysts Offer Predictions for PolyPid Ltd.’s Q3 2024 Earnings (NASDAQ:PYPD) - Defense World
HC Wainwright Reiterates “Buy” Rating for PolyPid (NASDAQ:PYPD) - Defense World
Polypid Ltd (PYPD) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):